20:37 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Effector reports Phase I/II data for eFT508 in hematological malignancies

Effector Therapeutics Inc. (San Diego, Calif.) reported data from 10 evaluable patients with hematological malignancies in a Phase I/II trial showing that eFT508 led to one partial response in a patient with non-germinal center B...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
04:50 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S....
18:36 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1 - MKNK2 - eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1...
02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
14:06 , Jul 24, 2017 |  BC Extra  |  Financial News

Effector raises $38.6M in series C

Cancer company Effector Therapeutics Inc. (San Diego, Calif.) raised $38.6 million in a series C round led by new investor Pfizer Venture Investments. Also participating were new investor Alexandria Venture Investments and existing investors U.S....
20:16 , Jul 7, 2017 |  BC Week In Review  |  Company News

Effector combining EFT508 and Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) will conduct an open-label, Phase II trial evaluating EFT508 with or without PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) in patients with microsatellite stable...
07:00 , Aug 15, 2016 |  BioCentury  |  Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
01:15 , Feb 20, 2016 |  BC Extra  |  Financial News

Effector expands series B round

Effector Therapeutics Inc. (San Diego, Calif.) raised an additional $16 million in series B funding, bringing the round's total to $56 million. The new funds came from new investor Sectoral Asset Management, as well as...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

eFT508: Phase I/II started

Effector began an open-label, dose-escalation, dose-expansion, U.S. Phase I/II trial to evaluate oral eFT508 once daily in 21-day cycles in about 120 patients. The company expects data from the dose-escalation portion this summer. Effector Therapeutics...